Literature DB >> 3920734

Squamous cell carcinoma of the anal canal: treatment by external beam irradiation.

F Eschwege, P Lasser, A Chavy, P Wibault, J Kac, P Rougier, C Bognel.   

Abstract

External beam radiation therapy alone or in combination with curietherapy is the recommended treatment for anal canal carcinoma in some countries. In others, surgery is the sole accepted treatment. The results for 64 patients treated by external radiotherapy alone show excellent survival for stage T1T2 tumors but results are poor for large tumors (stage T4). The overall 5 year crude survival rate is 46%. The 5-year results are better for stage T1T2 (72%) than for stage T3T4 (35%). The presence of inguinal node involvement at first examination is a very poor prognostic sign. Local recurrences and metastases are infrequent for stage T1T2, but are more common for stage T3 and T4. Complications follow radiotherapy more frequently in those with stage T3 and T4 tumors. The analysis of local recurrences, complications and survival shows that radiation therapy may be sufficient treatment for stage T1 and T2 and for some stage T3 tumors. The importance of anal sphincter involvement and the poor quality of life for patients who are cured but develop complications, shows the need for combined treatment with surgery and perhaps with chemotherapy. For small tumors the results obtained by external radiotherapy alone are comparable with those obtained by external radiotherapy and curietherapy in terms of survival and complications.

Entities:  

Mesh:

Year:  1985        PMID: 3920734     DOI: 10.1016/s0167-8140(85)80019-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Combined radiation and chemotherapy for epidermoid carcinoma of the anal canal.

Authors:  I H Schneider; G G Grabenbauer; T Reck; F Köckerling; R Sauer; F P Gall
Journal:  Int J Colorectal Dis       Date:  1992-12       Impact factor: 2.571

Review 2.  Treatment of primary epidermoid carcinoma of the anal canal.

Authors:  B J Cummings
Journal:  Int J Colorectal Dis       Date:  1987-06       Impact factor: 2.571

Review 3.  Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.

Authors:  Guillaume Klausner; Eivind Blais; Raphaël Jumeau; Julian Biau; Mailys de Meric de Bellefon; Mahmut Ozsahin; Thomas Zilli; Raymond Miralbell; Juliette Thariat; Idriss Troussier
Journal:  Med Oncol       Date:  2018-08-20       Impact factor: 3.064

4.  SEOM clinical guidelines for the treatment of anal cancer.

Authors:  Joan Maurel; Carlos Fernández-Martos; Jaime Feliu; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

5.  [Intracavitary afterloading therapy as a new technique of boost irradiation in anal canal carcinoma].

Authors:  O Kölbl; K Bratengeier; S Richter; R Henkel; R Schmidt; M Flentje
Journal:  Strahlenther Onkol       Date:  1997-10       Impact factor: 3.621

Review 6.  State of the art: gastrointestinal malignancies in the human immunodeficiency virus (HIV) population.

Authors:  Mary Koshy; John Kauh; Clifford Gunthel; Melissa Joyner; Jerome Landry; Charles R Thomas
Journal:  Int J Gastrointest Cancer       Date:  2005

7.  Endoanal ultrasonography in the follow-up of anal carcinoma.

Authors:  U Herzog; M Boss; H P Spichtin
Journal:  Surg Endosc       Date:  1994-10       Impact factor: 4.584

Review 8.  Anal cancer: multimodal therapy.

Authors:  P M Schlag; M Hünerbein
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

9.  Induction chemotherapy with carboplatin and 5-fluorouracil in combination with radiotherapy in loco-regionally advanced epidermoid carcinoma of the anus--preliminary results.

Authors:  C Svensson; M Kaigas; S Goldman
Journal:  Int J Colorectal Dis       Date:  1992-09       Impact factor: 2.571

10.  Prognostic factors for squamous cell cancer of the anal canal.

Authors:  Prajnan Das; Christopher H Crane; Cathy Eng; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.